Study of CT1190B CAR-T Cell Therapy in Adults 18 to 75 Years with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Evaluating Safety, Treatment Effectiveness, and Cellular Behavior

What this Trial Is About

Researchers are evaluating the safety, effectiveness, and cellular metabolism of CT1190B CAR-T cell therapy in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma B-NHL. This is an early-phase, single-arm, open-label clinical study enrolling between 6 and 24 participants to explore how these specialized immune cells behave and impact the disease. Participants will receive an infusion of CT1190B CAR-T cells as the experimental treatment. The study focuses on assessing the dose range and safety within 28 days after infusion. It includes monitoring overall response and remission rates at 4 weeks, 8 weeks, 12 weeks, and then at 6, 9, and 12 months post-infusion. During the study, participants will undergo regular evaluations including safety assessments for adverse events up to 12 months after infusion. Researchers will monitor response times, duration of remission, progression-free survival, and overall survival over one year. Long-term follow-up is planned for up to 15 years to gather extended safety and efficacy data. Participants will be closely observed through scheduled visits and tests throughout the study period.

A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma